Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Antibe Therapeutics Inc(Pre-Merger) ATBPF

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.


GREY:ATBPF - Post by User

Comment by Marky1on Sep 11, 2020 10:36pm
273 Views
Post# 31547737

RE:Our old friend Robbie

RE:Our old friend RobbieWow...that was great Robbie! I have been in school now ( Online, sadly ) and I just read all the posts  of the last few days

I am still very bullish on ATE...great science backs us up.  Great statistical  numbers proving our superiority in dosage, efficacy, minimal GI effects.
we have an unbelievable product, the greatest drug invention in the last 50 years!

1) Concerning who I'd like to see, and hope, buys us out...I think Pfizer would be a much better choice...They are an American Company...They trade on an American Exchange...They have 10B$ cash on hand...They know the hospitals, clinics, the Doctors. They have, I'm sure, experience with the FDA...If not a buyout, then a partnership for P3 testing would be very welcomed .Bayer is not an American company...They have 6B$ cash on hand..They need their money to help pay their law suits against them..Perhaps a bidding war? Who knows

2) concerning the price tag..Companies going into P3 testing usually have a Market Cap of 600M$USD...This was confirmed to me by IR and reiterated in the BioPub talk...doing the math that works out to be 2.06$cdn....exactly what the average target price is at...coincidence?? I think not

3) According to Dan, the valuation of ANTIBE should be evaluated by its estimated peak sales...that's 4B$...Now if a company sees that, then how much should the offer for Otenaproxesul...I'd say at least 1B$ usd...probably a lot more

4) the NSAIDs market is roughly 15B$ a year business and growing...Dan says that a company with a new drug can expect to capture about 20% of the market...That's 3B$USD...just phenomenal 

5) I see an amazing 2021 !!  Phase 3 starting Q2021...Entrance onto Nasdaq Q3.... SP 2.06$ by July 1st 2021

good luck all good people stay safe and patience is golden!

Before a Tsunami hits, the water recedes, then WHAM
Great futur!

Bullboard Posts